-+ 0.00%
-+ 0.00%
-+ 0.00%

ALPHA TAU ANNOUNCES FDA APPROVAL TO EXPAND ALPHA DART® U.S. RECURRENT GLIOBLASTOMA REGAIN TRIAL; NEW TRIAL DATA TO BE PRESENTED AT SNO 2026 ANNUAL MEETING

Reuters·10/19/2026 12:30:01

Please log in to view news